Skip to main content

Missouri PQC Regional Meeting

Event Details

April 17, 2024
9:00am – 3:30pm

In-person location in St. Louis and virtual (see below).

Register on or before Wednesday, April 10, to ensure the delivery of instructional materials.

Register Online
A mother kissing the forehead of a newborn baby in her arms.


Missouri is seeing increasing rates of substance use disorder among pregnant and postpartum people, which contributes to severe maternal and infant morbidity and mortality. While serving birthing people with SUD can be complex, the Missouri PQC is committed to providing opportunities for clinicians and community-based providers to increase Missouri’s capacity to treat maternal-infant dyads affected by SUD. This one-day session will focus on increasing understanding and ability for buprenorphine initiation and titration techniques, as well as address the unique pain management considerations for pregnant and postpartum people with opioid use disorder. The Missouri PQC is bringing together all regions of the state — both in-person and virtually — to learn from experts and collaborate with regional partners on practical approaches to managing care for perinatal patients with an SUD.

Additional Information

Live In Person:
Marriott St. Louis West
660 Maryville Centre Drive
St. Louis, MO 63141

A Zoom option also is available.

Physicians, nurses, prescribing providers who work with the perinatal population, community-based organizations, community birth workers, health care and clinic leaders, peer recovery coaches

Upon completion of this program, participants will be able to:

  • Learn practical approaches to managing care for perinatal patients with SUDs
  • Increase understanding and ability for buprenorphine initiation and titration techniques, as well as address the unique pain management considerations for pregnant and postpartum people with opioid use disorder

To support collaboration and coordination between hospitals and community partners, this event is complimentary to all attendees.

9 a.m. – Registration: Check-in for both in-person and virtual attendees
9:30 a.m. – Workshop Session: Buprenorphine Initiation and Titration Techniques During Pregnancy and Postpartum: How Do I Get This Going?

9:30 – 10 a.m. – Buprenorphine: Induction and Management in Pregnancy

10 – 10:30 a.m. – Advanced Buprenorphine Initiation Techniques and Management of Precipitated Withdrawal

10:30 – 11 a.m. – Transitioning to Postpartum Care and Alternative Formulations

11– 11:30 a.m. – Case-based Examples for Navigating Buprenorphine Initiation and Titration

11:30 a.m. – noon – Q&A and Audience Participation across all sites, both in-person and virtual

Noon – Networking Lunch

Lunch provided for in-person attendees at each location.
Virtual attendee networking will be facilitated by region.

1 p.m. – Workshop Session: Pain Management Considerations for Patients with OUD

1 – 1:30 p.m. – Best Practices for Intrapartum and Peripartum Anesthesia/Analgesia for Patients With OUD

1:30 – 2 p.m. – Postpartum Pain Management and Opioid Prescribing After Giving Birth

2 – 2:30 p.m. – Special Circumstances: Kidney Stones, Degenerating Fibroids, Osteomyelitis, Patients on Naltrexone

2:30 – 3 p.m. – Case-based Examples Focused on Navigating Pain Management in the Peripartum Period

3 – 3:30 p.m. – Q&A and Audience Participation across all sites, both in-person and virtual

3:30 p.m. – Adjournment

Dr. Niraj R. Chavan, M.D., MPH, FACOG, FASAM, is an Associate Professor in the Division of Maternal Fetal Medicine, Dept. of Obstetrics, Gynecology and Women’s Health at Saint Louis University (SLU). Dr. Chavan serves as the Medical Director for the Women and Infant Substance Help (WISH) Center at SLU, SSM Health, in St. Louis, Mo., focused on providing comprehensive, high-risk maternity care and substance use recovery services for women with perinatal substance use disorders. He also serves as the Program Director for the Maternal Fetal Medicine Fellowship, as well as core faculty for the Addiction Medicine Fellowship program at SLU – the only such ACGME-approved fellowship in the entire state of Missouri. Additionally, Dr. Chavan recently has designed and serves as the course director for a 4th year medical school elective on “Perinatal Addiction and Maternal Mental Health” through the SLU School of Medicine. Dr. Chavan is Board Certified in Obstetrics & Gynecology, Maternal Fetal Medicine and Addiction Medicine and is actively involved in clinical care, research and education related to perinatal SUDs in the academic and community setting.

Dr. Chavan currently serves as the chair-elect for the Missouri Pregnancy-Associated Mortality Review board and is an active member of the Missouri PQC. Dr. Chavan has presented several didactic sessions on the practical aspects of perinatal SUD management as a part of the ongoing Care for the Pregnant and Parenting People with Substance Use Disorder (CPPPSUD) AIM Bundle implementation across Missouri through the Missouri Hospital Association. He has led nationally attended CME webinar series on perinatal SUD treatment through Project ECHO (Extension for Community Healthcare Outcomes) programs and currently serves as course faculty for the “Mothers, Infants and NAS” ECHO as a part of the Show-Me ECHO program through the Missouri Telehealth Network, University of Missouri.

Dr. Cresta Jones, M.D., FACOG, FASM, is an associate professor of maternal fetal medicine at the University of Minnesota Medical School. She also is board certified in addiction medicine, and her clinical and research work focuses on the intersection of pregnancy, substance use disorder, and discrimination and stigma.

She has presented at state, tribal and regional levels on best practices for patients affected by perinatal substance use, including for lactation. She recently served with Dr. Chavan to co-host the first ever postgraduate course on perinatal substance use disorder? for the Society of Maternal Fetal Medicine.

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and MHA Health Institute.  AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

This activity was planned by and for the healthcare team, and learners will receive 5.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for a maximum of 5.0 contact hours. 

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity. 

AXIS Contact Information
For information about the accreditation of this program please contact AXIS at 

Disclosure of Relevant Financial Relationships
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.  

AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. 

The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

  • Niraj R. Chavan, M.D., MPH, FACOG, FASAM: Nothing to disclose
  • Cresta Jones, M.D., FACOG, FASM: Nothing to disclose

The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: 

  • Alex Shikles: Nothing to disclose
  • Rachel Allen: Nothing to disclose
  • Allison Williams: Nothing to disclose
  • Ronald Viggiani, MD: Nothing to disclose
  • Holly M. Hampe, DSc., RN, MHA, MRM, CPHQ: Nothing to disclose
  • Dee Morgillo, MEd., MT(ASCP), CHCP: Nothing to disclose

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Requirements for credit:   

  • Attend/participate in the educational activity and review all course materials.  
  • Complete the CE Attestation/Evaluation form online by 11:59 pm ET on May 17, 2024.  Instructions will be provided. If you do not complete the online evaluation by this date, you will not be able to get CME/CE credit for this event. 
  • Upon successful completion of the online form, your statement of completion will be presented to you to print.  

Please note that your registration request will be submitted to the organizer for approval. Upon approval, instructional materials will be sent to the email address indicated on the registration form.

If you have special needs addressed by the Americans With Disabilities Act, please contact the Missouri Hospital Association.

MHA Health Institute
P.O. Box 60
Jefferson City, MO 65102
Phone: 573-893-3700
Fax: 573-893-2809

Event Contact

A headshot of Rachel Allen, Grant Specialist.

Rachel Allen

Grants and Project Manager


Register on or before Wednesday, April 10, to ensure the delivery of instructional materials.